Profound Medical Corp.
A maker of MRI-guided ultrasound systems that destroy diseased tissue with no incisions or radiation. Its TULSA-PRO ablates prostate cancer and tumors from inside the urethra, while Sonalleve tackles uterine fibroids, bone pain, and other conditions. The company grew out of Toronto's Sunnybrook Research Institute in 2008 and later acquired Sonalleve from Philips — a name blending "son" (ultrasound) with "alleviate," fitting for a device that erases tumors with focused sound waves.
Bought 22.0K
| Insider | Stake change | Holds now | Granted / vested | Bought | Sold |
|---|---|---|---|---|---|
| Menawat Arun SwarupCEO, Director · 2 transactions | — | 587.1Kas of May 2025 | — | 22.0K | — |
Select a row to see that insider’s individual transactions.
Net open-market activity over all recorded history: +22.0K shares. Grants, option exercises and tax withholding are excluded — they are compensation mechanics, not decisions to buy or sell.